Le Lézard
Classified in: Health
Subject: NPT

Canada Health Infoway Selects Simeio for Identity, Access and Consent as a Service (IACaaS)


TORONTO, Jan. 27, 2020 /CNW/ - Canada Health Infoway (Infoway) is pleased to announce that it has selected Simeio Solutions (Simeio) as the technical solution provider for the new Identity, Access and Consent as a Service (IACaaS). Infoway and its collaborators across Canada will leverage these services to provide Canadians with improved access to health care services, and greater control over their digital health information.

"Digital identity is the starting point for enabling Canadians to better manage their health care," said Michael Green, President and CEO, Infoway. "Simeio's innovative approach, advanced capabilities and capacity will enable Infoway to offer Canadian solution developers an innovative patient-centric user experience for identity, access and consent. This will give Canadians greater convenience and more control over their personal health information."

The Simeio solution will be part of Infoway's ACCESS Health program that is uniting industry, health care providers, provinces, territories and Canadians to redefine where and how Canadians access digital health services and their personal health information.

Simeio will support the development of an identity service, which when incorporated or federated with existing products and services will enable users to control how they retrieve their digital health records and who else can access them.

Key components of IACaaS:

"This is one of Simeio's largest deployment within the health care industry," said Asif Mohamed Savvas, Senior Vice President, Simeio Solutions. "Working with Infoway gives us a greater footprint and enhances our capabilities, strengthening our position as a leading customer identity and access management (CIAM) and identity and access management (IAM) provider. With this nationwide deployment of identity, access and consent, Canadians have a path to improving their health outcomes through enhanced digital health care. We're providing a single set of identity credentials, for secure data management and retrieval."

About Canada Health Infoway

Infoway helps improve the health of Canadians by working with partners to accelerate the development, adoption and effective use of digital health across Canada. Through our investments, we help deliver better quality and access to care, and more efficient delivery of health services for patients and clinicians. Infoway is an independent, not-for-profit organization funded by the federal government. Visit https://www.infoway-inforoute.ca/en/.

Media Inquiries

Karen Schmidt                                                                       
Director, Corporate/Internal Communications
Canada Health Infoway
416.595.3167
Email Us
Follow @Infoway

SOURCE Canada Health Infoway


These press releases may also interest you

at 03:00
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, today announced an oral presentation at the upcoming Oligonucleotide & Peptide Therapeutics (TIDES) Conference...

at 02:32
With every successive year, the lines between medical devices and consumer electronics become increasingly blurred ? medtech companies seek to expand their reach beyond patients, and consumer electronics companies have targeted medical applications...

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...



News published on and distributed by: